Second Sight Medical Products Inc. has completed its merger with Nano Precision Medical Inc.
Second Sight a developer of implantable visual prosthetics intended to create an artificial form of useful vision for blind individuals. NPM is a biopharmaceutical business that develops miniaturized subdermal drug implants using its NanoPortal technology for delivery of medicines to treat chronic diseases.
In connection with the merger, Second Sight changed its name to Vivani Medical Inc. The company’s common stock will trade on the Nasdaq Capital Market under the symbol “VANI.”
Upon completion of the merger, Vivani has approximately $55 million in cash to advance the development of its portfolio. It’s seeking to move lead asset NPM-119 (exenatide implant) into clinical-stage development for the treatment of patients with Type 2 diabetes and to advance its clinical-stage Orion visual prosthetic device to treat individuals with blindness.
